MP Advisors is a Consultancy firm with an exclusive focus on Pharmaceuticals / Biotechnology sectors in the US, Europe, India, Japan and Russia. It was operating earlier as an international affiliate of Mehta Partners LLC since 1996. Today it has a highly motivated, qualified team of PhDs, MBAs and Pharmacist who apply their domain knowledge to develop proprietary data bases, understand dynamic regulatory laws across geographies, track and analyze latest trends in drug development, clinical trials and specific diseases.
 
MP Advisors has insightful information on more than 200 pharma and Biotech companies around the globe as well as publishes reports on Key Opinion Leaders (Physician’s view) assessment, therapy class review of several classes (e.g. Oral anticoagulants, Hepatitis C, Obesity, Novel Drug Delivery systems, Biosimilars etc.), India and Japan generic opportunities and Paragraph IV Opportunities.

Page

Next Decade Generic String Of Pearls Opportunities: Sustainability Assessment With Respect To Therapeutic Positioning

By MP Advisors | Healthcare | Nov 2017 | Page 124

The rapid growth of the generic industry has come with a number of challenges, such as heavy competition, including from authorized generics and government-mandated price cuts. All contribute to diminishing....

USD 4000 View Report

The Future of the U.S. Biologics and Biosimilars Treatment Market for Psoriasis

By MP Advisors | Healthcare | Oct 2017 | Page 104

The new report from MP Advisors titled The Future of the U.S. Biologics and Biosimilars Treatment Market for Psoriasis examines in detail the current treatment landscape and the outlook through....

USD 4000 View Report

Japan Biosimilars – A start of Authorized Biosimilar Era? Biosimilar/BioPharma CMO opportunities – JP Conglomerates – A definite role to play for Global Market! Major JP Innovator vs. Early entrant Mid size Japanese companies- TA focus approach – A Win Win Game!

By MP Advisors | Pharmaceuticals and Healthcare | Aug 2017 | Page 128

Get key upcoming opportunity for Japan BS market, its competitive landscape, and current trend of biosimilars use in Japan.....

USD 4000 View Report

Prostate Cancer -Newer Antiandrogens & Emerging Therapies Targeting a “Watchful Waiting” and Resistance Population

By MP Advisors | Healthcare | Feb 2017 | Page 200

This report details current unmet need, changing regulatory requirement, reimbursement challenges & market dynamics of Prostate Cancer drugs. Report mention pipeline Antiandrogens, late stage prostate cancer pipeline drugs/new Mechanism of....

USD 4500 View Report

Hepatitis C Virus Infection

By MP Advisors | Healthcare | Oct 2013 | Page 33

Freedom from injecting Interferon (IFN), treating major HCV genotypes WW and betting on vaccines could bring a sea of change in the treatment of HCV infection in the future. This....

USD 1000 View Report